Navigation Links
Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, presented first-time data from a pre-clinical study evaluating the toxicity and antitumor effect of nab-rapamycin (ABI-009), an albumin-bound mTOR kinase inhibitor, at the 98th American Association for Cancer Research (AACR) Annual Meeting held April 14-18, 2007 in Los Angeles. Results from the pre-clinical study demonstrated that nab-rapamycin was well-tolerated, showed linear pharmacokinetics, and was highly effective against a number of tumor models in vivo. (Abstract #4719; Nanoparticle Albumin-bound (nab) Rapamycin as an Anticancer Agent).

Leveraging Nab Technology with Rapamycin to Target mTOR Pathway

The mammalian target of rapamycin (mTOR) is a cell-signaling protein that regulates the response of tumor cells to nutrients and growth factors, as well as controls tumor blood supply through effects on vascular endothelial growth factor (VEGF). Rapamycin is an mTOR inhibitor. The mTOR pathway is thought to be overactivated in numerous tumors and plays a critical role in cell survival and resistance to chemotherapy. Inhibition of mTOR activity prevents the signaling to important pathways that control cell growth and lead to a lowering of VEGF levels, thus decreasing the ability of tumors to gain their own blood supply (angiogenesis).

The role of mTOR inhibition has led investigators at Abraxis to explore the use of the nanoparticle albumin-bound (nab(TM)) tumor-targeting technology to enhance the deregulation of mTOR signaling. Nab-rapamycin is also intended to address limitations posed by the poor water solubility of rapamycin and may enable higher concentrations of the drug to reach the tumor tissue. Abraxis plans to commence Phase I clinical trials with nab-rapamycin in 2007.

Abraxis continues to explore the role of nab technology for targeting SPARC an
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
2. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:10/31/2014)... , Oct. 31, 2014 ThynkWare ( ... (ALS) patients initiate text and email messages using their ... patent-pending technology invented by ThynkWare,s founder, Duane Cash ... a smartphone device. This technology allows users to control ... the power of thought. ThynkWare provides the ...
(Date:10/31/2014)... /CNW Telbec/ - Ergoresearch Ltd ("Ergoresearch" or ... accelerated growth in terms of sales and profitability. Annual ... Net income amounted to $1,230,153. The EBITDA reached $3,087,816, ... in the Company,s history. With the goal ... of its subsidiaries, merging in September 2014 Clinique du ...
(Date:10/31/2014)... 31, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... , Isis Pharmaceuticals, Third Quarter 2014 Financial Results ... at 11:30 a.m. ET / 8:30 a.m. PTWhere: ... Internet. Simply log onto our website listed above. If ... a replay of the webcast will be available for ...
Breaking Medicine Technology:ThynkWare Speech Helps Those with ALS and Locked-In Syndrome Translate Thought to Speech on Their Smartphone Devices 2Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 2Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 3Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 4Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 5Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3
... 2012  In a single bound, Nepean Cancer Care Centre ... its prostate cancer cases to a dramatically faster therapy ... technique that is even quicker with Elekta,s new Integrity™ ... their first patient with prostate cancer using Integrity on ...
... CSL Behring is the recipient of ... developing and manufacturing therapies used to treat rare and ... in plasma-derived and recombinant therapies used to treat congenital ... disease, is a subsidiary of CSL Limited ...
Cached Medicine Technology:Australian Clinic Puts Prostate Cancer Radiation Therapy on Fast Track With Elekta VMAT and Integrity Digital Control System 2Australian Clinic Puts Prostate Cancer Radiation Therapy on Fast Track With Elekta VMAT and Integrity Digital Control System 3CSL Behring Recognized as a "Pioneer" By European Organisation for Rare Diseases (EURORDIS) 2
(Date:10/31/2014)... St. Joseph, Missouri (PRWEB) October 31, 2014 ... prepare for school, one Midwest optometrist feels they may ... vision problems to affect areas like concentration, school performance ... events may be too brief to identify progressive vision ... Options, St. Joseph, Mo., announces a new initiative: The ...
(Date:10/31/2014)... Oct. 31, 2014 (HealthDay News) -- Obesity increases the ... black and Hispanic women, two new U.S. studies show. ... found being overweight or obese increased the risk for ... women. "We,ve known this for a long time ... also in Hispanic women," study author Esther John, a ...
(Date:10/31/2014)... Santa Barbara, CA (PRWEB) October 31, 2014 ... for holiday shoppers to find affordable but tasteful gifts for ... special 22nd Annual Early Bird Gift Giving Special , ... percent off when they purchase Wine Club Gift membership. ... to take advantage of this special. Besides offering discounts, Gold ...
(Date:10/31/2014)... 2014 Florida Air Academy, the ... in grades 6-12, is taking the lead when ... and concussions, becoming the first high school in ... Post-Concussion Assessment and Cognitive Testing) computerized assessment to ... lawsuit grabs the headlines, and the Centers for ...
(Date:10/31/2014)... 31, 2014 BCC Research ( http://www.bccresearch.com ) ... QUALITY MARKET , the U.S. indoor air quality (IAQ) market ... a compound annual growth rate (CAGR) of 7% over the ... grow at a CAGR of 7.4%. , Since 2012, ... mold, the outbreak of infectious diseases such as bird flu ...
Breaking Medicine News(10 mins):Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Study Confirms Obesity-Breast Cancer Link for Blacks, Hispanics 2Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:Florida Air Academy Tackling Concussions Head-On 2Health News:Florida Air Academy Tackling Concussions Head-On 3Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 2Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 3
... , FRIDAY, Jan. 14 (HealthDay News) -- Obese ... doctors than obese white patients, a new study finds. ... Public Health also said they were surprised to find that ... to receive weight and exercise counseling than black patients treated ...
... A simple, automated method of tracking E. coli ... potentially contaminated bodies of water or waterways. The technique described ... and Drug Design could reduce the incidence of waterborne ... environmental and health problem. Water related diseases are the leading ...
... COLUMBUS, Ohio A new study by Ohio State ... cancer by combining two kinds of targeted agents, one ... and one that reverses changes that silence genes that ... available and being evaluated individually in clinical trials, the ...
... THURSDAY, Jan. 13 (HealthDay News) -- Home-based dialysis is an ... say. In a new study, researchers evaluated the impact ... the survival of 2,110 adult Canadian patients who had to ... were similar for both groups of patients during the initial ...
... Association today issued a call to action for the public, ... efforts to reduce the amount of sodium (salt) Americans consume ... Journal of the American Heart Association , the association sets ... the general population, which is to consume no more than ...
... , THURSDAY, Jan. 13 (HealthDay News) -- In an unscripted ... Tucson and America" memorial, President Barack Obama said Rep. Gabrielle ... and her husband Mark Kelly at University Medical Center in ... to House Minority Leader Nancy Pelosi (D-Calif.) confirmed that Pelosi, ...
Cached Medicine News:Health News:Is Race a Factor in Obesity Counseling? 2Health News:Speeding up E. coli detection 2Health News:Study provides molecular rationale for combining targeted agents to treat breast cancer 2Health News:Dialysis Options Remain After Kidney Transplant Failure 2Health News:Population-wide reduction in salt consumption recommended 2Health News:Population-wide reduction in salt consumption recommended 3Health News:Giffords Opens Eyes. Like 'Watching a Miracle,' Friends Say 2Health News:Giffords Opens Eyes. Like 'Watching a Miracle,' Friends Say 3
The Panorama Central Station includes bi-directional communication with Datascope bedside monitors, optional 72 hours of disclosure and a touch screen user interface....
... The MedSystem III DLE (Drug List ... dimension to drug infusion technology. The instrument ... features and clinical versatility in an unparalleled ... Calculation, the MedSystem III Infusion System simplifies ...
... One of the first steps any ... to offer the most powerful, most effective ... Acute Care, CliniComps world-class clinician documentation and ... and health systems achieve this goal. In ...
... Essentris Critical Care, the world-class clinician ... reflects decades of focus on the specific ... critical care environments. Its broad, deep clinical ... leading documentation and EMR solution in critical ...
Medicine Products: